Single-target MET TKIs

Single-target MET tyrosine kinase inhibitors (TKIs) are precision oncology therapies designed to inhibit signaling driven by MET alterations, including exon 14 skipping and, in selected settings, MET amplification or overexpression. Their clinical value depends on accurate biomarker identification, appropriate treatment sequencing, and management of class-related adverse events. The field is shaped by advances in molecular diagnostics, regulatory differentiation across jurisdictions, and the need to position targeted treatment within increasingly complex lung-cancer care pathways.

The principal shift is from broad histology-based treatment selection toward molecularly defined care. MET exon 14 skipping is a clinically actionable alteration in non-small-cell lung cancer, while the relevance of amplification and overexpression is more context-dependent and requires careful assay interpretation. Treatment decisions increasingly depend on validated next-generation sequencing, specimen quality, turnaround time, and concordance between tissue and liquid-biopsy results. Other transformative factors include intracranial disease management, resistance monitoring, and the integration of targeted therapy with immunotherapy, chemotherapy, and local interventions.

Artificial intelligence can improve the practical delivery of MET-directed care by supporting variant annotation, detecting difficult splice alterations, prioritizing potentially actionable findings, and reducing manual review in pathology and molecular laboratories. Predictive models may also help identify patients at risk of progression, central nervous system involvement, or treatment intolerance. However, clinical value depends on representative training data, transparent validation, interoperability with laboratory systems, and prospective evidence that AI-assisted decisions improve outcomes. AI should therefore augment multidisciplinary review rather than replace oncologists, pathologists, or molecular geneticists.

North America generally combines advanced molecular testing, established oncology networks, and comparatively broad access to targeted therapies, although reimbursement and disparities remain important constraints. Europe benefits from sophisticated clinical research and guideline infrastructure, while access and testing capacity differ across European countries. Asia-Pacific contains major innovation and manufacturing capabilities alongside substantial variation in diagnostic availability and healthcare financing. Latin America faces uneven access to comprehensive genomic testing and specialized care. The Middle East is investing in precision-medicine capacity, but coverage differs across health systems. Africa continues to face shortages in molecular diagnostics, oncology infrastructure, and specialist workforce, making referral networks and scalable testing especially important.

The G7 combines strong research ecosystems with mature regulatory and reimbursement institutions, but national evidence requirements still influence uptake. The European Union benefits from cross-border scientific collaboration, while implementation remains affected by country-level health-technology assessment and diagnostic access. BRICS members represent diverse healthcare systems, manufacturing capabilities, and levels of genomic readiness; coordinated investment can improve access but does not eliminate local disparities. ASEAN markets vary considerably in reimbursement, laboratory infrastructure, and specialist availability. GCC countries are strengthening centralized and digitally enabled healthcare systems, whereas NATO membership itself does not create a uniform oncology-access framework; participating countries retain distinct regulatory and funding arrangements.

The United States and Canada have strong precision-oncology capabilities, with access influenced by payer policy, testing pathways, and specialist referral. Australia, Japan, and South Korea combine advanced oncology infrastructure with established molecular diagnostics, although approval and reimbursement processes differ. China has substantial clinical-research and pharmaceutical capacity, alongside regional variation in access and testing. India, Brazil, Mexico, and Russia face differing challenges involving affordability, laboratory coverage, and geographic concentration of specialist care. France, Germany, Italy, Spain, and the United Kingdom have robust clinical networks, but national assessment, procurement, and diagnostic-reimbursement mechanisms shape real-world availability. Across all countries, rapid identification of MET alterations and equitable access to confirmatory testing remain central priorities.

Industry leaders should align therapeutic development with analytically validated biomarker strategies, including clear definitions of MET exon 14 skipping and clinically meaningful approaches to amplification. They should strengthen tissue and liquid-biopsy pathways, publish transparent evidence for intracranial activity and resistance management, and design trials that reflect real-world comorbidity and prior-treatment patterns. Partnerships with laboratories, health systems, and patient organizations can improve testing completion and treatment navigation. Operationally, leaders should invest in pharmacovigilance, drug–drug interaction education, adherence support, and clinician training, while using AI only within auditable governance frameworks. Access strategies should address diagnostic affordability and regional infrastructure rather than focusing solely on medicine availability.

This executive summary uses a structured review of authoritative clinical guidelines, peer-reviewed studies, regulatory documents, biomarker research, health-system publications, and publicly available diagnostic standards. Evidence was interpreted by separating established findings for MET exon 14 skipping from less consistent evidence concerning amplification and overexpression. Regional, group, and country observations were synthesized from documented differences in healthcare infrastructure, molecular-testing capacity, regulatory practice, and reimbursement conditions. No market estimates, market shares, forecasts, or company-specific claims are included. Conclusions should be updated as trial results, regulatory decisions, diagnostic validation, and treatment guidelines evolve.

Single-target MET TKIs have reinforced the role of biomarker-defined treatment in thoracic oncology, particularly for patients whose tumors harbor actionable MET alterations. The next phase of progress will depend less on therapeutic selectivity alone and more on reliable testing, rapid interpretation, equitable access, resistance-aware sequencing, and evidence generation across diverse populations. Health systems and industry leaders that connect diagnostics, clinical expertise, data governance, and patient support will be best positioned to translate MET biology into consistent clinical benefit.